GHRP-2 Acetate — Potent GH Secretagogue | Growth Hormone Research
GHRP-2 (Pralmorelin) is a synthetic hexapeptide GHRP that activates GHSR-1a to stimulate pulsatile GH release with high potency. As the most potent of the classic GHRPs alongside Hexarelin, GHRP-2 has been extensively studied in clinical trials for GH deficiency diagnosis and treatment — providing a robust evidence base. Unlike Ipamorelin, GHRP-2 also modestly stimulates cortisol, prolactin, and ACTH, which must be accounted for in research design.
Available Formats
- 10mg
- 5mg
Reconstitution: Reconstitute with Bacteriostatic Water (BAC Water) for multi-use stability, or Sterile Water for single-use protocols. Store lyophilized vials at 2–8°C.
Key Research Areas
⚡ Maximum GH Pulse Induction
GHRP-2 produces among the highest GH pulses of all synthetic GHRPs. Clinical studies demonstrate 3–15x baseline GH elevation. Research applications include GH stimulation testing, GH deficiency research, and maximum GH output protocols.
🍽️ Appetite & Ghrelin Research
GHRP-2 activates ghrelin receptors, producing measurable increases in appetite and food intake in research models. This makes GHRP-2 a reference compound for hunger signalling, ghrelin physiology, and eating behaviour research.
❤️ Cardioprotection Research
Cardioprotective effects of GHRP-2 have been documented in ischemia-reperfusion models — independent of GH release. Studies suggest direct cardiac receptor activation and anti-apoptotic effects in cardiomyocytes.
💪 IGF-1 & Anabolic Research
Strong GH pulse induction drives IGF-1 elevation, lean tissue accretion, and fat mobilization in research models. Combined with GHRH analogues, GHRP-2 produces exceptional GH/IGF-1 axis activation.
Why Choose EhBuddy?
- ✅ Verified Purity — Third-party tested
- ✅ Fast Canadian Shipping — Discreet packaging
- ✅ Research-Grade Quality — Strict QC standards
FOR RESEARCH USE ONLY (RUO). Not approved for human or veterinary use. Intended for in vitro and laboratory research only.














Reviews
There are no reviews yet.